



## IOL CHEMICALS AND PHARMACEUTICALS LIMITED

14<sup>th</sup> November 2024  
IOLCP/CGC/2024

**National Stock Exchange of India Ltd.**  
Exchange Plaza, Plot no. C/1, G Block,  
Bandra-Kurla Complex, Bandra (E)  
Mumbai - 400 051  
**Security Symbol: IOLCP**

**BSE Limited**  
Phiroze Jeejeebhoy Towers,  
Dalal Street  
Mumbai- 400 001  
**Security Code: 524164**

**Subject: Press Release: Financial Results for the quarter and half year ended 30<sup>th</sup> September 2024.**

Dear Sir,

Pursuant to Regulation 30 read with Schedule III of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015, please find enclosed a Press Release dated 14<sup>th</sup> November 2024 with respect to financial results for the quarter and half year ended 30<sup>th</sup> September 2024.

Hope you will find the same in order.

Thanking You,

Yours faithfully,  
for IOL Chemicals and Pharmaceuticals Limited

Abhay Raj Singh  
Sr. Vice President & Company Secretary



IOL Chemicals And Pharmaceuticals Limited

For immediate release

## IOL Chemicals and Pharmaceuticals Reports Q2 & H1-FY25 Results

14<sup>th</sup> November 2024, Ludhiana:

IOL Chemicals and Pharmaceuticals Ltd, a leading manufacturer of pharmaceutical APIs and speciality chemicals, announced its financial results for the second quarter and half year ended 30<sup>th</sup> September 2024.

### Standalone Q2-FY25 Financial Highlights (₹ in Crore)

Particulars	Q2 FY25	Q1 FY25	% QoQ	Q2 FY24	% YoY
Total Income	532.18	509.76	4.40	552.41	-3.66
EBITDA	47.99	58.18	-17.51	71.21	-32.61
EBITDA Margin (%)	9.02%	11.41%	-240 bps	12.89%	-387 bps
PAT	19.15	29.68	-35.48	37.79	-49.33
PAT Margin (%)	3.60%	5.82%	-222 bps	6.84%	-324 bps

### Standalone H1-FY25 Financial Highlights (₹ in Crore)

Particulars	H1 FY25	H1 FY24	% YoY
Total Income	1041.94	1122.65	-7.19
EBITDA	106.17	151.13	-29.75
EBITDA Margin (%)	10.19%	13.46%	-327 bps
PAT	48.83	84.00	-41.87
PAT Margin (%)	4.69%	7.48%	-280 bps

The CARE Ratings Limited reaffirmed the credit ratings for the enhanced banking facilities from Rs.600 Crore to Rs.700 Crore at **CARE A+** with **Stable** outlook.



## IOL Chemicals And Pharmaceuticals Limited

Commenting on the performance, **Mr Vikas Gupta, Joint Managing Director** said, "We are pleased to report sustainable revenue growth in Q2 FY25, reflecting the resilience of our core business. However, we faced some margin pressure during the quarter, driven by challenges in selling price. To address this, we are taking proactive measures to optimize marketing strategies, cost structure and enhance operational efficiencies, with the goal of improving profitability in the coming periods. Despite these challenges, we remain confident in the long-term growth potential of the business."

### **About IOL Chemicals and Pharmaceuticals Limited (IOLCP)**

Established in 1986 and listed on the National Stock Exchange of India Ltd (Code: IOLCP) and BSE Ltd (Code: 524164), IOL Chemicals and Pharma is one of the leading pharmaceutical (APIs) Companies and a significant player in the specialty chemicals space with world-class facilities. IOLCP has a wide presence across major therapeutic categories like pain management, anti-convulsants, anti-diabetes, anti-cholesterol and anti-platelets.

The Company's product portfolio includes APIs; Ibuprofen, Metformin, Fenofibrate, Clopidogrel, Lamotrigine, Pantoprazole, Paracetamol and specialty chemicals such as Ethyl Acetate, Iso Butyl Benzene, Mono Chloro Acetic Acid, Acetic Anhydride and Acetyl Chloride.

The company is the World's largest producer of Ibuprofen with an installed capacity of 12,000 TPA and having backward integrated manufacturing facility. The Company has DSIR-approved R&D which is fully equipped to validate existing processes.

The Central and State Government approved Effluent Treatment Plant (ETP) had been set up with Zero Liquid Discharge (ZLD) system along with a 17 MW captive Co-Generation plant for self-reliance. The Company is ISO 9001:2015, 14001:2015 and BS OHSAS 18001:2007 certified.

IOLCP's overseas customers are spread out across several countries including the UK, Belgium, Hungary, Spain, Germany, Italy, Netherlands, Switzerland, Poland, Ireland, USA, Peru, Brazil, Argentina, Colombia, Indonesia, South Korea, Thailand, Bangladesh, Turkey, U.A.E., China, Hong Kong, Egypt etc. Products are sold primarily to Branded Generic formulators both in India & Overseas.

### **Disclaimer:**

*This document may contain statements which reflect management's current views and estimates and could be construed as forward-looking statements. The future involves certain risks and uncertainties and could cause actual results to differ materially from the current views being expressed. Potential risks and uncertainties include factors such as general economic conditions, foreign exchange fluctuation, pricing pressures, competition and regulatory developments.*